Fudan-Zhangjiang Bio-Pharmaceutical's Profit, Revenue Drop in 2024
MT Newswires Live03-28
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349, SHA:688505) profit attributable to shareholders in 2024 fell to 39.7 million yuan or 0.0383 yuan per share, from 108.6 million yuan or 0.1051 yuan per share, according to a Hong Kong Stock Exchange disclosure on Thursday.
The Chinese pharmaceutical company's revenue slipped to 709.4 million yuan from 850.7 million yuan a year earlier, the disclosure said.
The board of directors proposed a dividend of 0.03 yuan per share to be paid on Aug. 25 to shareholders registered by July 12.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
